| Literature DB >> 35158181 |
Rita Murri1, Carlotta Masciocchi2, Jacopo Lenkowicz2, Massimo Fantoni3, Andrea Damiani4, Antonio Marchetti5, Paolo Domenico Angelo Sergi5, Giovanni Arcuri6, Alfredo Cesario2, Stefano Patarnello2, Massimo Antonelli7, Rocco Bellantone8, Roberto Bernabei9, Stefania Boccia10, Paolo Calabresi11, Andrea Cambieri12, Roberto Cauda3, Cesare Colosimo13, Filippo Crea14, Ruggero De Maria15, Valerio De Stefano16, Francesco Franceschi8, Antonio Gasbarrini8, Raffaele Landolfi8, Ornella Parolini17, Luca Richeldi18, Maurizio Sanguinetti19, Andrea Urbani19, Maurizio Zega20, Giovanni Scambia10, Vincenzo Valentini16.
Abstract
BACKGROUND: The COVID-19 pandemic affected healthcare systems worldwide. Predictive models developed by Artificial Intelligence (AI) and based on timely, centralized and standardized real world patient data could improve management of COVID-19 to achieve better clinical outcomes. The objectives of this manuscript are to describe the structure and technologies used to construct a COVID-19 Data Mart architecture and to present how a large hospital has tackled the challenge of supporting daily management of COVID-19 pandemic emergency, by creating a strong retrospective knowledge base, a real time environment and integrated information dashboard for daily practice and early identification of critical condition at patient level. This framework is also used as an informative, continuously enriched data lake, which is a base for several on-going predictive studies.Entities:
Mesh:
Year: 2022 PMID: 35158181 PMCID: PMC8800500 DOI: 10.1016/j.cmpb.2022.106655
Source DB: PubMed Journal: Comput Methods Programs Biomed ISSN: 0169-2607 Impact factor: 7.027
Fig. 1Generator infrastructure to create and automatically update the COVID-19 Data Marts from Operational Data Warehouses and Production Databases.
Fig. 2simplified view of patient-centered COVID-19 Data Mart in place at Policlinico Gemelli.
Characteristic of the study population as of January 5st 2022.
| Characteristics | All patients ( | Alive ( | Died ( | p-value | |
|---|---|---|---|---|---|
| Demographics | Age, median(SD) | 65.0 (19.0) | 62.0 (18.8) | 80.0 (11.8) | |
| Male | 3066 (55.5%) | 2566 (54.9%) | 500 (58.6%) | 0.02 | |
| BMI, median (IQR) | 25.9 (23.4; 28.7) | 25.9 (23.5; 28.7) | 25.7 (23.4; 28.4) | 0.1 | |
| Coexisting Conditions | Any | 3158 (57%) | 2507 (54%) | 651 (76%) | <0.01 |
| Current or Former Smoker | 108 (2.0%) | 101 (2.2%) | 7 (0.8%) | 0.01 | |
| Arteriopathy | 61 (1.1%) | 39 (0.8%) | 22 (2.6%) | <0.01 | |
| Chronic Liver Disease | 55 (1.0%) | 47 (1.0%) | 8 (0.9%) | 1 | |
| Cirrhosis | 46 (0.8%) | 33 (0.7%) | 13 (1.5%) | 0.02 | |
| Dyslipidemia | 373 (6.7%) | 310 (6.6%) | 63 (7.4%) | 0.4 | |
| HIV | 94 (1.7%) | 85 (1.8%) | 9 (1.1%) | 0.1 | |
| Myocardial Infarction | 665 (12.0%) | 481 (10.3%) | 184 (21.6%) | <0.01 | |
| Kidney Failure | 323 (5.8%) | 207 (4.4%) | 116 (13.6%) | <0.01 | |
| Hypertension | 2013 (36.4%) | 1628 (34.8%) | 385 (45.1%) | <0.01 | |
| Autoimmune Disease | 245 (4.4%) | 210 (4.5%) | 35 (4.1%) | 0.6 | |
| Hematologic Neoplasm | 87 (1.6%) | 60 (1.3%) | 27 (3.2%) | <0.01 | |
| Neurologic Impairment | 486 (8.8%) | 309 (6.6%) | 177 (20.8%) | <0.01 | |
| Pancreatitis | 37 (0.7%) | 28 (0.6%) | 9 (1.1%) | 0.2 | |
| Cardiovascular Pathology | 865 (15.6%) | 609 (13.0%) | 256 (30.0%) | <0.01 | |
| Lung Pathology | 531 (9.6%) | 372 (8.0%) | 159 (18.6%) | <0.01 | |
| Heart Failure | 245 (4.4%) | 148 (3.2%) | 97 (11.4%) | <0.01 | |
| Hepatic Ulcer | 106 (1.9%) | 69 (1.5%) | 37 (4.3%) | ||
| Symptoms At Admission | Any | 4102 (74.2%) | 3454 (73.9%) | 648 (76.0%) | 0.2 |
| Cough | 1523 (27.6%) | 1381 (29.5%) | 142 (16.6%) | <0.01 | |
| Dyspnea | 2535 (45.9%) | 2051 (43.9%) | 484 56.7%) | <0.01 | |
| Fever | 3393 (61.4%) | 2910 (62.2%) | 483 (56.6%) | <0.01 | |
| Nausea or Vomiting | 247 (4.5%) | 221 (4.7%) | 26 (3.0%) | 0.03 | |
| Diarrhea | 372 (6.7%) | 338 (7.2%) | 34 (4.0%) | <0.01 | |
| Time From Symptom Onset to Admission, median (IQR) | 8 (3; 366) | 9 (4; 366) | 5 (2; 11) | <0.01 | |
| Vital Signs on the Day of Admission, median (IQR) | Temperature, °C | 36.4 (36.0; 37.5) | 36.4 (36 0.0; 37.6) | 36.3 (36.0; 37.5) | 0.01 |
| Systolic Blood Pressure, mm Hg | 129.0 (115.0; 140.0) | 130.0 (116.0; 140.0) | 130.0 (116.0; 140.0) | <0.01 | |
| Laboratory Findings on the Day of Admission, median (IQR) | White Blood Cell Count, /µL | 7.4 (5.4; 10.4) | 7.3 (5.4; 10.1) | 8.4 (5.8; 12.0) | <0.01 |
| Lymphocyte Count, /µL | 1.1 (0.7; 1.5) | 1.1 (0.8; 1.5) | 0.9 (0.6; 1.3) | <0.01 | |
| Hemoglobin Level, g/dL | 13.4 (11.8; 14.7) | 13.5 (12.0; 14.8) | 12.6 (10.8; 14.0) | <0.01 | |
| Platelets, µL | 208.0 (161.0; 272.0) | 211.0 (164.0; 274.0) | 191.0 (142.0; 259.5) | <0.01 | |
| Creatinine Level, mg/dL | 0.9 (0.7; 1.1) | 0.8 (0.7; 1.1) | 1.1 (0.8; 1.8) | <0.01 | |
| D-dimer level, ng/mL | 846.0 (460.0; 1874.0) | 764.0 (427.0; 1620.0) | 1606.5 (794.5; 3686.0) | <0.01 | |
| C-reactive protein level, mg/L | 60.1 (23.9; 121.4) | 52.9 (21.1; 110.7) | 99.3 (50.2; 160.6) | <0.01 | |
| Urea Nitrogen, mg/dL | 18.0 (13.0; 27.0) | 17.0 (13.0; 23.0) | 30.0 (21.0; 47.0) | <0.01 | |
| Albumin, g/L | 32.0 (29.0; 35.0) | 33.0 (29.0; 36.0) | 29.0 (25.0; 32.0) | <0.01 | |
| Vitamin D, ng/mL | 17.1 (12.1; 27.7) | 17.3 (12.4; 27.7) | 15.2 (8.6; 27.3) | 0.2 | |
| P/F | 232.1 (152.8; 333.3) | 247.5 (162.9; 340.0) | 163.3 (109.5; 266.7) | <0.01 | |
Fig. 3Conceptual view of Dashboard profiling for General Use, Hospital Management, Ward and Patient Care.
Fig. 4A. Weekly retrospective overview of cohort, split by wards, compared with non-COVID-19 inpatients evolution. Fig. 4B Daily view of new hospitalized patients, total patients in charge, filtered view of outcomes.
Fig. 5A. Cumulative clinical dashboard displaying incidence of comorbidities, average age for inpatients over time, symptoms and evolution of average days of symptoms onset. Fig. 5B Drill down for the historical cohort of COVID-19 patients with evolution over time of IL-6 at baseline and comparison with most recent hospitalized patients. Fig. 5C. Same dashboard as 5B for D-Dmer.
Fig. 6A. Summary ward dashboard: newly hospitalized, total in charge, transfer to ICU, split by outcome. Fig. 6B Drill-down at war: historical compare with current average PaO2/FiO2 ratio and length of stay; list of patients with alert flag for most critical cases. Fig. 6C. Patient drill-down dashboard example, providing history of PaO2/FiO2 ratio and fever, last outcome of TC, swab sequence and days from symptom onset.